XiFin's AI Offensive: New CTO and Surging Growth Signal RCM Revolution

SAN DIEGO, CA – February 24, 2026 – XiFin, Inc. is signaling a major escalation in its mission to overhaul healthcare's financial backbone, reporting robust double-digit growth in 2025 and appointing a new Chief Technology Officer to accelerate its artificial intelligence strategy. The San Diego-based health-tech leader saw a remarkable 21.1% increase in transaction volume through its XiFin Empower RCM platform, a clear indicator of the market's growing appetite for AI-driven solutions to combat mounting financial pressures.

The appointment of Sanjay Kumar as the new CTO is the centerpiece of this strategic push. With Kumar at the technology helm, XiFin aims to deepen the integration of AI and automation across its entire ecosystem, a move its leadership describes as fundamental to defining the next era of healthcare financial operations.

A Strategic Pivot to AI-Driven Infrastructure

XiFin's leadership is framing its recent success not just as strong performance, but as evidence of a larger market evolution. "Our performance in 2025 reflects more than strong results—it signals a structural shift toward intelligent, AI-driven revenue cycle infrastructure," said Lâle White, XiFin's Executive Chair and Chief Executive Officer. This shift is a direct response to the escalating financial and operational complexity that healthcare organizations face, from tightening reimbursement models to persistent administrative burdens.

Sanjay Kumar has been brought on to spearhead the technical execution of this vision. His resume includes over two decades of scaling cloud-native and AI-driven platforms, most recently as CTO for ResMed’s $800 million Residential Care Software business. There, he led a complex, multi-year transformation that unified disparate product portfolios—including MatrixCare and Brightree—into a cohesive, single cloud-native platform. This experience is directly applicable to XiFin's goal of creating an interoperable AI ecosystem.

"Bringing Sanjay onto our leadership team strengthens our ability to execute on that vision, advancing cloud-native innovation and positioning XiFin to help define the next era of healthcare financial operations," White added. Kumar's expertise in embedding machine learning and generative AI into clinical and revenue cycle workflows is expected to be instrumental as XiFin expands its advanced AI capabilities into emerging markets like Medical Devices and Durable Medical Equipment (DME).

"XiFin’s momentum, combined with its commitment to AI‑powered innovation, makes this an extraordinary time to join the organization," Kumar stated. "The company’s technology foundation delivers measurable impact for clients, and there is enormous potential to extend that impact with next‑generation AI, agentic capabilities, and automation capabilities."

Market Validation and Investor Confidence

The company's strategic direction is heavily fortified by concrete performance metrics and significant financial backing. In 2025, XiFin recorded 16.4% growth in its crucial molecular diagnostics segment and 13.3% growth in its hospital segment. These figures, combined with the surge in Empower RCM volume, paint a picture of a company rapidly gaining market share.

This momentum has not gone unnoticed by the investment community. In 2025, XiFin secured a new round of growth capital led by the Goldman Sachs External Investing Group, with participation from its majority investor, Avista Healthcare Partners. While the financial details were not disclosed, the involvement of a global financial powerhouse like Goldman Sachs serves as a powerful endorsement of XiFin's AI-centric strategy and long-term vision for healthcare infrastructure. The investment provides the company with significant financial flexibility to continue its aggressive innovation and market expansion.

Client adoption further validates the platform's impact. Global laboratory leader Sonic Healthcare expanded its use of XiFin's solutions across multiple divisions last year. Meanwhile, precision medicine innovator Caris Life Sciences has publicly endorsed the tangible productivity gains achieved through the platform. These high-profile partnerships underscore the Empower RCM solution's ability to handle complex, high-volume revenue cycle operations for industry leaders. Independent analysis and customer testimonials suggest that clients can see a 4% increase in net collection rates and a 20-30% average increase in cash collections within their first year.

Dominance Backed by Data and Accolades

XiFin's market leadership is not just self-proclaimed; it is consistently affirmed by independent research and a steady stream of industry accolades. For the seventh consecutive year, Black Book Market Research named XiFin the #1 client-rated leader for RCM outsourcing in its 2025 survey, covering cross-ancillary and outpatient laboratory services. The company also secured the top spot for outpatient radiology and diagnostic imaging RCM for the second year.

The Black Book report, which is based on surveys from over 3,200 validated users, highlighted AI-driven denial prevention and tight clinical-to-billing integration as key differentiators for top-performing vendors. XiFin's high scores in delivering actionable analytics, reducing claim denials, and accelerating claims resolution directly reflect the real-world benefits of its technology.

Further bolstering its credentials, XiFin achieved HITRUST i1 Certification for its key pharmacy systems, reinforcing its commitment to the highest standards of cybersecurity and data protection. The company was also featured in RXinsider’s 2026 Pharmacy500, listed among Silicon Review’s “Global Best Companies to Watch in 2025,” and recognized by Insights Care as a top RCM company.

This strategic rigor extends to its governance. The company recently added Jeff Margolis, a veteran healthcare IT executive, to its Board of Directors. Margolis founded TriZetto, the industry's first vertical SaaS platform, and his deep experience in scaling healthcare technology companies adds another layer of strategic oversight to XiFin's ambitious plans.

Shaping the Broader Healthcare Ecosystem

Beyond its commercial success, XiFin is actively working to influence the broader healthcare landscape through industry engagement and advocacy. The company's decision to join the Pharmacy Interoperability and Clinical Services Alliance (PICSA) demonstrates a commitment to advancing interoperability standards and empowering pharmacists to operate as integrated clinical care providers.

Through this and other collaborative efforts, XiFin is helping to shape the frameworks that govern data exchange and clinical service delivery. This work is critical for enabling diagnostics providers and pharmacies to play a more central and effective role in patient care.

The company also contributes to the industry's knowledge base with its own comprehensive research. It recently introduced the inaugural 2025 Specialty Pharmacy Transformation Outlook and published the 2025 Payor Denial Impact Report, which analyzes millions of claims to provide one of the industry's most detailed views of denial trends. By equipping healthcare leaders with this actionable intelligence, XiFin positions itself not merely as a solutions provider, but as a strategic partner dedicated to improving the financial health and operational efficiency of the entire healthcare system.